Moore H
Semin Thromb Hemost. 2022; 49(5):433-443.
PMID: 36318960
PMC: 10366941.
DOI: 10.1055/s-0042-1758057.
Liu L, Wang Y, Li Y, Lin Y, Hou Y, Zhang Y
PLoS One. 2016; 11(9):e0162317.
PMID: 27637099
PMC: 5026343.
DOI: 10.1371/journal.pone.0162317.
Barve A, Jin W, Cheng K
J Control Release. 2014; 187:118-32.
PMID: 24878184
PMC: 4079732.
DOI: 10.1016/j.jconrel.2014.05.035.
Nieves E, Manchanda N
J Biol Chem. 2010; 285(17):12595-603.
PMID: 20177061
PMC: 2857136.
DOI: 10.1074/jbc.M109.008581.
Belorgey D, Hagglof P, Karlsson-Li S, Lomas D
Prion. 2009; 1(1):15-20.
PMID: 19164889
PMC: 2633702.
DOI: 10.4161/pri.1.1.3974.
Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.
Zhang H, Morisaki T, Matsunaga H, Sato N, Uchiyama A, Hashizume K
Clin Exp Metastasis. 2001; 18(4):343-52.
PMID: 11448066
DOI: 10.1023/a:1010897432244.
Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay R, Kuemmel T, ORLANDO R, Farquhar M
Mol Biol Cell. 2001; 12(5):1467-79.
PMID: 11359936
PMC: 34598.
DOI: 10.1091/mbc.12.5.1467.
Different Effects of Lipopolysaccharide on Plasminogen Activator Inhibitor-1 Production in Aortic Media in Vivo and in Culture.
van Leeuwen RT , Quax , Tippins , Antoniw , Andreotti , Maseri
J Thromb Thrombolysis. 1996; 3(3):215-223.
PMID: 10613985
DOI: 10.1007/BF00181664.
Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance.
Vaughan
J Thromb Thrombolysis. 1995; 2(3):187-193.
PMID: 10608023
DOI: 10.1007/BF01062709.
Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices.
Kroon M, Koolwijk P, van Goor H, Weidle U, Collen A, van der Pluijm G
Am J Pathol. 1999; 154(6):1731-42.
PMID: 10362798
PMC: 1866643.
DOI: 10.1016/S0002-9440(10)65429-6.
Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.
Vilhardt F, Nielsen M, Sandvig K, van Deurs B
Mol Biol Cell. 1999; 10(1):179-95.
PMID: 9880335
PMC: 25162.
DOI: 10.1091/mbc.10.1.179.
Ligand-binding domains in vitellogenin receptors and other LDL-receptor family members share a common ancestral ordering of cysteine-rich repeats.
Sappington T, Raikhel A
J Mol Evol. 1998; 46(4):476-87.
PMID: 9541543
DOI: 10.1007/pl00006328.
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Allgayer H, Babic R, Grutzner K, Beyer B, Tarabichi A, Schildberg F
Clin Exp Metastasis. 1998; 16(1):62-73.
PMID: 9502078
DOI: 10.1023/a:1006564002679.
Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves....
Rodenburg K, Kjoller L, Petersen H, Andreasen P
Biochem J. 1998; 329 ( Pt 1):55-63.
PMID: 9405275
PMC: 1219013.
DOI: 10.1042/bj3290055.
Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Waltz D, Natkin L, Fujita R, Wei Y, Chapman H
J Clin Invest. 1997; 100(1):58-67.
PMID: 9202057
PMC: 508165.
DOI: 10.1172/JCI119521.
Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions.
ORLANDO R, Exner M, Czekay R, Yamazaki H, Saito A, Ullrich R
Proc Natl Acad Sci U S A. 1997; 94(6):2368-73.
PMID: 9122201
PMC: 20094.
DOI: 10.1073/pnas.94.6.2368.
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H
Am J Pathol. 1997; 150(4):1231-44.
PMID: 9094980
PMC: 1858180.
Clustered folate receptors deliver 5-methyltetrahydrofolate to cytoplasm of MA104 cells.
Smart E, Mineo C, Anderson R
J Cell Biol. 1996; 134(5):1169-77.
PMID: 8794859
PMC: 2120971.
DOI: 10.1083/jcb.134.5.1169.
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Mohanam S, Sawaya R, Yamamoto M, Bruner J, Nicholson G, Rao J
J Neurooncol. 1994; 22(2):153-60.
PMID: 7745467
DOI: 10.1007/BF01052890.
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.
Namiranian S, Naito Y, Kakkar V, Scully M
Biochem J. 1995; 309 ( Pt 3):977-82.
PMID: 7639718
PMC: 1135727.
DOI: 10.1042/bj3090977.